Scope and Claims Breakdown for US Patent 6,689,761 (Combination of Compound J, 3TC, and AZT) and the U.S. Patent Landscape

US Patent 6,689,761 is a combination patent built around a three-component antiviral regimen in the U.S.: a specific “Compound J” plus lamivudine (3TC) and zidovudine (AZT), with claims extending to both method-of-treatment and pharmaceutical composition. The claim set is broad on “combination” scope and administration timing (simultaneously or alternatively), while narrower on the identity of “Compound J” (not specified in the claim text provided).

What is US Patent 6,689,761 and what does it claim protect?

Answer: It protects a regimen combining “Compound J” with 3TC and AZT, and covers (i) the combination product concept, (ii) administration methods (simultaneous or alternative dosing), and (iii) compositions for inhibiting HIV protease and HIV reverse transcriptase and treating HIV/AIDS/ARC.

What are the core claim elements?

Claim 1 anchors all dependent claims:

Component A: “Compound J” (nucleoside analog HIV reverse transcriptase inhibitor per the provided claim framing)
Component B: 3TC (lamivudine)
Component C: AZT (zidovudine)
Claim 1 scope: includes pharmaceutically acceptable salts or esters of the above combination

From there, the patent expands to:

Methods of use (claims 2–6)
Composition claims (claims 7–9)

How broadly does “combination” read?

Based on the claim text supplied, the combination is not limited by:

dose ratio
total daily dose
fixed-dose vs kit-of-separately-packaged actives
route of administration (e.g., oral vs parenteral)
patient population (no restriction beyond “suitable mammal”)

The only explicit administration constraints appear in dependent claims:

Simultaneous dosing (claim 2)
Alternative dosing (claim 3)

Is there a built-in mechanism linkage?

Claims 4–6 assign utility to the combination:

Claim 4: inhibits HIV protease
Claim 5: inhibits HIV reverse transcriptase
Claim 6: treats HIV, AIDS or ARC

From the claim language alone, the patent is drafted to support multiple antiviral mechanism labels. That matters for enforcement: if a generic or competitor argues the regimen is only intended for reverse transcriptase suppression, the independent utility claims still target protease inhibition.

How do the independent and dependent claims map to enforceable IP coverage?

Answer: Claim 1 is the product combination anchor. Claims 2–3 create “timing” variants. Claims 4–6 create “use” variants (protease inhibition, reverse transcriptase inhibition, clinical treatment). Claims 7–9 create formulation and composition coverage tied to the same combination.

Claim 1 (combination definition) as the anchor

“A combination of compounds, which is Compound J, 3TC, and AZT…”

This is a composition-of-actives claim dressed as a “combination.” For infringement in typical U.S. practice, this structure tends to capture:

fixed-dose combination products
co-administered regimens where all claimed actives are present in the treatment course

The scope hinges on what “Compound J” is in the specification. The claim text you provided does not state its chemical identity, but the patent’s enforceability in practice depends on that disclosure.

Claim 2 and Claim 3 (administration timing)

Claim 2: “administered simultaneously”
Claim 3: “administered alternatively”

This duality is designed to prevent an easy “workaround” by switching to staggered dosing schedules. A competitor that markets a regimen with the same three actives but uses staggered administration risks falling into one of these dependent claims.

Claims 4–6 (method-of-use)

Claim 4: “inhibiting HIV protease”
Claim 5: “inhibiting HIV reverse transcriptase”
Claim 6: “treating infection by HIV, AIDS or ARC”

These utility claims broaden enforcement options. They also create regulatory and labeling relevance: if a product label supports one of these therapeutic statements, it can strengthen a patentee’s position.

Claims 7–9 (pharmaceutical compositions)

Claim 7: composition useful for inhibiting HIV protease
Claim 8: composition useful for inhibiting HIV reverse transcriptase
Claim 9: composition useful for treating HIV/AIDS/ARC

These are not just “methods”; they are direct product-form coverage. If a competitor’s product contains the claimed combination (again anchored on “Compound J”), composition claims can be asserted even if the competitor differentiates dosing timing.

Does the claim language cover both fixed-dose and co-packaged regimens?

Answer: Yes, based on the provided claim language, because the claims describe “combination of compounds” and timing (“simultaneously” vs “alternatively”) without limiting dosage form packaging architecture.

What the claims do not restrict

From the claim text provided, the patent does not specify:

whether the actives must be in one dosage form
whether it must be a fixed-dose tablet/capsule
whether it is a kit with separate dosage forms

That absence matters in enforcement. If the “combination” is interpreted as a treatment regimen rather than a single physical dosage unit, then co-administration models can still infringe.

What does the patent likely cover from a chemical/functional standpoint?

Answer: A regimen where “Compound J” is a nucleoside analog HIV reverse transcriptase inhibitor, used in combination with 3TC and AZT, with claimed therapeutic utility spanning protease inhibition and reverse transcriptase inhibition.

Why “protease” appears in a nucleoside-analog centered claim set

Nucleoside reverse transcriptase inhibitors primarily target reverse transcriptase. The claim’s inclusion of HIV protease inhibition suggests one of two drafting approaches common in older antiretroviral patent families:

The specification provides support that the claimed combination yields or is claimed to yield protease inhibition.
The patentee used broader utility labeling to capture antiviral activity beyond the primary biochemical target.

Either way, the claim text you supplied makes “protease inhibition” an explicit claimed method and composition utility.

How strong is the patent’s scope for blocking competitors?

Answer: The scope is strong on regimen-level capture (three actives together, administration timing, and therapeutic utility) but depends heavily on the identity of “Compound J” and how narrowly that identity is defined in the specification and related dependent claims not provided here.

What would be required to avoid infringement

A generic or competitor typically avoids by:

omitting one claimed component (easy on paper if “Compound J” is not present)
changing the active identity such that “Compound J” is not met
changing the treatment so that it does not fall within the claimed method categories (less feasible for composition claims)

Because the claims include both method and composition, avoiding infringement usually requires more than changing dosing schedule.

What is the likely patent estate structure around US 6,689,761?

Answer: US 6,689,761 appears to be a “core combination” patent within a family that likely includes related claims covering the chemical entity (“Compound J”), its salts/esters, and formulation or method-of-use variants. The claim set you provided is combination-centered, implying the patent is part of a broader antiretroviral IP web.

Common adjacency in combination antiretroviral families

Even without the rest of the record, combination patents like this commonly sit alongside:

Entity patents: synthesis and composition of “Compound J” itself
Salt/ester patents: pharmaceutically acceptable forms
Formulation patents: delivery system, excipients, dosage forms
Additional combination patents: substitutions of partner nucleosides or different dosing ratios/timing

This matters commercially: a product that “works around” the combination claim can still run into an entity or formulation wall.

What US Orange Book status should be expected for this patent?

Answer: A combination patent covering actives that are likely older (AZT and 3TC) typically appears in Orange Book listings only if it is tied to a specific approved NDA/ANDA product and formulation.

Because you did not provide the drug product(s) tied to US 6,689,761’s Orange Book listing, no definitive Orange Book status can be stated from the claim text alone.

When does the patent lose exclusivity under U.S. law?

Answer: The U.S. patent expiration date depends on its filing date and term adjustments, which are not provided in the claim excerpt.

Without the patent’s application filing date, patent term adjustment (PTA), or any terminal disclaimers, the exact “lose exclusivity” date cannot be determined from the information supplied.

What generic entry risks exist for combinations including 3TC and AZT?

Answer: The generic entry risk is high if a generic product includes the claimed “Compound J” plus 3TC and AZT in a regimen that supports the claimed therapeutic uses, because the patent covers both administration timing and composition.

Where Paragraph IV or non-infringing design-arounds would focus

For generic or biosimilar-style challenges (though this is small-molecule, not biologics), the practical risk analysis focuses on:

Whether the generic includes “Compound J” in any form claimed (including salts/esters if those forms are defined as within “Compound J”)
Whether the generic’s label or promotional claims align with “treating HIV, AIDS or ARC” and utility statements
Whether manufacturing and packaging still result in the combination being administered within the claimed timing windows

How does this patent interact with later antiretroviral standards of care?

Answer: It targets an older-era nucleoside backbone (AZT + 3TC) in combination with a third agent (“Compound J”). Modern antiretroviral regimens are typically different (e.g., single-tablet regimens, integrase-based backbones), so the practical infringement risk depends on whether the market still uses this exact three-agent regimen.

The patent’s legal scope is regimen-precise, but its real-world relevance depends on what “Compound J” corresponds to and whether it remains used in approved therapies.

Litigation and enforcement posture: what would this patent be used for?

Answer: Based on the claim architecture (product combination + method + composition), it is structured for:

injunction claims targeting regimen products that include all claimed actives
damages claims for pre-launch or post-launch use tied to labeled indications
enforcement against manufacturing and product sales that produce the claimed composition

The specific litigation history (district, case number, settlement terms) cannot be identified from the claim excerpt provided.

Comparison: what would be a competitive “look-alike” threat?

Answer: A competitor that markets a treatment regimen containing the same actives (Compound J + 3TC + AZT) with either simultaneous or alternative administration is the clearest risk profile for infringement.

High-risk scenarios

fixed-dose products containing all three actives
co-packaged products where the regimen results in administration of all three actives within the dosing patterns captured by claims 2–3
labels and instructions for use that match claim 6 (HIV/AIDs/ARC treatment) and/or claim 4–5 utility statements

Lower-risk scenarios

regimens that omit “Compound J”
regimens that substitute one partner active so “3TC” or “AZT” is not present
alternative agents that avoid meeting “Compound J” identity (only feasible if “Compound J” is chemically narrow)

Key takeaways

US 6,689,761 is a three-active combination patent anchored on “Compound J” plus 3TC and AZT, covering both administration methods and pharmaceutical compositions.
The claims are designed to block timing workarounds via simultaneous (claim 2) and alternative (claim 3) administration.
The patent includes utility statements for both HIV protease and HIV reverse transcriptase, plus HIV/AIDS/ARC treatment (claims 4–6), which increases enforcement flexibility.
The practical enforceability against competitors is highly dependent on how “Compound J” is defined in the specification and whether competitors include that specific chemical entity (including salts/esters) in combination with 3TC and AZT.

FAQs

1. Does US 6,689,761 require fixed-dose co-formulation to infringe?
No. The claims provided cover “combination of compounds” and explicitly cover simultaneous or alternative administration, without requiring a single dosage unit.

2. Can a competitor avoid infringement by changing dosing schedule?
Claim 2 and claim 3 already cover simultaneous and alternative administration, so schedule changes alone are unlikely to avoid infringement if all actives are present in the regimen.

3. What therapeutic indications does US 6,689,761 cover?
It claims methods and compositions for treating HIV infection, AIDS, or ARC, and for inhibiting HIV protease and HIV reverse transcriptase.

4. Are salts and esters covered by claim scope?
Claim 1 includes “pharmaceutically acceptable salt or ester thereof” tied to the combination of Compound J, 3TC, and AZT.

5. What is the main infringement risk for a generic regimen using AZT and 3TC?
The main risk is inclusion of the third required component, “Compound J,” because the combination claims require all three actives to be present.

References

United States Patent 6,689,761. Claims text as provided by the user.

Title:	Combination therapy for HIV infection
Abstract:	The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Inventor(s):	Jeffrey A. Chodakewitz, Emilio A. Emini
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US08/382,113
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	Scope and Claims Breakdown for US Patent 6,689,761 (Combination of Compound J, 3TC, and AZT) and the U.S. Patent Landscape US Patent 6,689,761 is a combination patent built around a three-component antiviral regimen in the U.S.: a specific “Compound J” plus lamivudine (3TC) and zidovudine (AZT), with claims extending to both method-of-treatment and pharmaceutical composition. The claim set is broad on “combination” scope and administration timing (simultaneously or alternatively), while narrower on the identity of “Compound J” (not specified in the claim text provided). What is US Patent 6,689,761 and what does it claim protect? Answer: It protects a regimen combining “Compound J” with 3TC and AZT, and covers (i) the combination product concept, (ii) administration methods (simultaneous or alternative dosing), and (iii) compositions for inhibiting HIV protease and HIV reverse transcriptase and treating HIV/AIDS/ARC. What are the core claim elements? Claim 1 anchors all dependent claims: Component A: “Compound J” (nucleoside analog HIV reverse transcriptase inhibitor per the provided claim framing) Component B: 3TC (lamivudine) Component C: AZT (zidovudine) Claim 1 scope: includes pharmaceutically acceptable salts or esters of the above combination From there, the patent expands to: Methods of use (claims 2–6) Composition claims (claims 7–9) How broadly does “combination” read? Based on the claim text supplied, the combination is not limited by: dose ratio total daily dose fixed-dose vs kit-of-separately-packaged actives route of administration (e.g., oral vs parenteral) patient population (no restriction beyond “suitable mammal”) The only explicit administration constraints appear in dependent claims: Simultaneous dosing (claim 2) Alternative dosing (claim 3) Is there a built-in mechanism linkage? Claims 4–6 assign utility to the combination: Claim 4: inhibits HIV protease Claim 5: inhibits HIV reverse transcriptase Claim 6: treats HIV, AIDS or ARC From the claim language alone, the patent is drafted to support multiple antiviral mechanism labels. That matters for enforcement: if a generic or competitor argues the regimen is only intended for reverse transcriptase suppression, the independent utility claims still target protease inhibition. How do the independent and dependent claims map to enforceable IP coverage? Answer: Claim 1 is the product combination anchor. Claims 2–3 create “timing” variants. Claims 4–6 create “use” variants (protease inhibition, reverse transcriptase inhibition, clinical treatment). Claims 7–9 create formulation and composition coverage tied to the same combination. Claim 1 (combination definition) as the anchor “A combination of compounds, which is Compound J, 3TC, and AZT…” This is a composition-of-actives claim dressed as a “combination.” For infringement in typical U.S. practice, this structure tends to capture: fixed-dose combination products co-administered regimens where all claimed actives are present in the treatment course The scope hinges on what “Compound J” is in the specification. The claim text you provided does not state its chemical identity, but the patent’s enforceability in practice depends on that disclosure. Claim 2 and Claim 3 (administration timing) Claim 2: “administered simultaneously” Claim 3: “administered alternatively” This duality is designed to prevent an easy “workaround” by switching to staggered dosing schedules. A competitor that markets a regimen with the same three actives but uses staggered administration risks falling into one of these dependent claims. Claims 4–6 (method-of-use) Claim 4: “inhibiting HIV protease” Claim 5: “inhibiting HIV reverse transcriptase” Claim 6: “treating infection by HIV, AIDS or ARC” These utility claims broaden enforcement options. They also create regulatory and labeling relevance: if a product label supports one of these therapeutic statements, it can strengthen a patentee’s position. Claims 7–9 (pharmaceutical compositions) Claim 7: composition useful for inhibiting HIV protease Claim 8: composition useful for inhibiting HIV reverse transcriptase Claim 9: composition useful for treating HIV/AIDS/ARC These are not just “methods”; they are direct product-form coverage. If a competitor’s product contains the claimed combination (again anchored on “Compound J”), composition claims can be asserted even if the competitor differentiates dosing timing. Does the claim language cover both fixed-dose and co-packaged regimens? Answer: Yes, based on the provided claim language, because the claims describe “combination of compounds” and timing (“simultaneously” vs “alternatively”) without limiting dosage form packaging architecture. What the claims do not restrict From the claim text provided, the patent does not specify: whether the actives must be in one dosage form whether it must be a fixed-dose tablet/capsule whether it is a kit with separate dosage forms That absence matters in enforcement. If the “combination” is interpreted as a treatment regimen rather than a single physical dosage unit, then co-administration models can still infringe. What does the patent likely cover from a chemical/functional standpoint? Answer: A regimen where “Compound J” is a nucleoside analog HIV reverse transcriptase inhibitor, used in combination with 3TC and AZT, with claimed therapeutic utility spanning protease inhibition and reverse transcriptase inhibition. Why “protease” appears in a nucleoside-analog centered claim set Nucleoside reverse transcriptase inhibitors primarily target reverse transcriptase. The claim’s inclusion of HIV protease inhibition suggests one of two drafting approaches common in older antiretroviral patent families: The specification provides support that the claimed combination yields or is claimed to yield protease inhibition. The patentee used broader utility labeling to capture antiviral activity beyond the primary biochemical target. Either way, the claim text you supplied makes “protease inhibition” an explicit claimed method and composition utility. How strong is the patent’s scope for blocking competitors? Answer: The scope is strong on regimen-level capture (three actives together, administration timing, and therapeutic utility) but depends heavily on the identity of “Compound J” and how narrowly that identity is defined in the specification and related dependent claims not provided here. What would be required to avoid infringement A generic or competitor typically avoids by: omitting one claimed component (easy on paper if “Compound J” is not present) changing the active identity such that “Compound J” is not met changing the treatment so that it does not fall within the claimed method categories (less feasible for composition claims) Because the claims include both method and composition, avoiding infringement usually requires more than changing dosing schedule. What is the likely patent estate structure around US 6,689,761? Answer: US 6,689,761 appears to be a “core combination” patent within a family that likely includes related claims covering the chemical entity (“Compound J”), its salts/esters, and formulation or method-of-use variants. The claim set you provided is combination-centered, implying the patent is part of a broader antiretroviral IP web. Common adjacency in combination antiretroviral families Even without the rest of the record, combination patents like this commonly sit alongside: Entity patents: synthesis and composition of “Compound J” itself Salt/ester patents: pharmaceutically acceptable forms Formulation patents: delivery system, excipients, dosage forms Additional combination patents: substitutions of partner nucleosides or different dosing ratios/timing This matters commercially: a product that “works around” the combination claim can still run into an entity or formulation wall. What US Orange Book status should be expected for this patent? Answer: A combination patent covering actives that are likely older (AZT and 3TC) typically appears in Orange Book listings only if it is tied to a specific approved NDA/ANDA product and formulation. Because you did not provide the drug product(s) tied to US 6,689,761’s Orange Book listing, no definitive Orange Book status can be stated from the claim text alone. When does the patent lose exclusivity under U.S. law? Answer: The U.S. patent expiration date depends on its filing date and term adjustments, which are not provided in the claim excerpt. Without the patent’s application filing date, patent term adjustment (PTA), or any terminal disclaimers, the exact “lose exclusivity” date cannot be determined from the information supplied. What generic entry risks exist for combinations including 3TC and AZT? Answer: The generic entry risk is high if a generic product includes the claimed “Compound J” plus 3TC and AZT in a regimen that supports the claimed therapeutic uses, because the patent covers both administration timing and composition. Where Paragraph IV or non-infringing design-arounds would focus For generic or biosimilar-style challenges (though this is small-molecule, not biologics), the practical risk analysis focuses on: Whether the generic includes “Compound J” in any form claimed (including salts/esters if those forms are defined as within “Compound J”) Whether the generic’s label or promotional claims align with “treating HIV, AIDS or ARC” and utility statements Whether manufacturing and packaging still result in the combination being administered within the claimed timing windows How does this patent interact with later antiretroviral standards of care? Answer: It targets an older-era nucleoside backbone (AZT + 3TC) in combination with a third agent (“Compound J”). Modern antiretroviral regimens are typically different (e.g., single-tablet regimens, integrase-based backbones), so the practical infringement risk depends on whether the market still uses this exact three-agent regimen. The patent’s legal scope is regimen-precise, but its real-world relevance depends on what “Compound J” corresponds to and whether it remains used in approved therapies. Litigation and enforcement posture: what would this patent be used for? Answer: Based on the claim architecture (product combination + method + composition), it is structured for: injunction claims targeting regimen products that include all claimed actives damages claims for pre-launch or post-launch use tied to labeled indications enforcement against manufacturing and product sales that produce the claimed composition The specific litigation history (district, case number, settlement terms) cannot be identified from the claim excerpt provided. Comparison: what would be a competitive “look-alike” threat? Answer: A competitor that markets a treatment regimen containing the same actives (Compound J + 3TC + AZT) with either simultaneous or alternative administration is the clearest risk profile for infringement. High-risk scenarios fixed-dose products containing all three actives co-packaged products where the regimen results in administration of all three actives within the dosing patterns captured by claims 2–3 labels and instructions for use that match claim 6 (HIV/AIDs/ARC treatment) and/or claim 4–5 utility statements Lower-risk scenarios regimens that omit “Compound J” regimens that substitute one partner active so “3TC” or “AZT” is not present alternative agents that avoid meeting “Compound J” identity (only feasible if “Compound J” is chemically narrow) Key takeaways US 6,689,761 is a three-active combination patent anchored on “Compound J” plus 3TC and AZT, covering both administration methods and pharmaceutical compositions. The claims are designed to block timing workarounds via simultaneous (claim 2) and alternative (claim 3) administration. The patent includes utility statements for both HIV protease and HIV reverse transcriptase, plus HIV/AIDS/ARC treatment (claims 4–6), which increases enforcement flexibility. The practical enforceability against competitors is highly dependent on how “Compound J” is defined in the specification and whether competitors include that specific chemical entity (including salts/esters) in combination with 3TC and AZT. FAQs 1. Does US 6,689,761 require fixed-dose co-formulation to infringe? No. The claims provided cover “combination of compounds” and explicitly cover simultaneous or alternative administration, without requiring a single dosage unit. 2. Can a competitor avoid infringement by changing dosing schedule? Claim 2 and claim 3 already cover simultaneous and alternative administration, so schedule changes alone are unlikely to avoid infringement if all actives are present in the regimen. 3. What therapeutic indications does US 6,689,761 cover? It claims methods and compositions for treating HIV infection, AIDS, or ARC, and for inhibiting HIV protease and HIV reverse transcriptase. 4. Are salts and esters covered by claim scope? Claim 1 includes “pharmaceutically acceptable salt or ester thereof” tied to the combination of Compound J, 3TC, and AZT. 5. What is the main infringement risk for a generic regimen using AZT and 3TC? The main risk is inclusion of the third required component, “Compound J,” because the combination claims require all three actives to be present. References United States Patent 6,689,761. Claims text as provided by the user. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	002957	⤷ Start Trial
Austria	243519	⤷ Start Trial
Australia	4774896	⤷ Start Trial
Australia	711176	⤷ Start Trial
Brazil	9607714	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,689,761

Summary for Patent: 6,689,761